Mobotinib (mobosetinib) enters medical insurance time

Mobocertinib (Mobocertinib), chemical name: EXK-3514, trade name: Exkivity, is an oral tyrosine kinase inhibitor (TKI) used to treat certain types of non-small cell lung cancer (NSCLC). It specifically targets patients who carry exon 20 insertion mutations in the EGFR (epidermal growth factor receptor) gene. This mutation is a rare type of EGFR gene mutation and is closely related to the development of lung cancer.

Mobotinib is now available in China, but it has not yet been included in medical insurance, so it is difficult to purchase it in China. For more detailed information, check with your local hospital or pharmacy. In the international market, there are both original drugs and generic drugs to choose from. Among them, original research drugs include the Hong Kong version of Japan's Takeda Pharmaceutical products, which cost about 7,000 to 8,000 yuan. Generic drugs, on the other hand, mainly come from Laos and Bangladesh. The price is relatively more affordable, about more than 3,000 yuan, which is nearly half cheaper than the original drugs, and their drug ingredients are basically the same as the original drugs.

The main mechanism of Mobotinib is to inhibit the tyrosine kinase activity of EGFR mutant protein and block the signal transduction pathway of cancer cells, thereby inhibiting the growth and spread of cancer cells. Unlike other TKIs that target EGFR mutations, mobotinib (mobosetinib) can effectively target exons pan>20Insertion mutations, which are often resistant to existing EGFR-TKIs, therefore mobosetinib (mobosetinib) provides a new treatment option for these patients.

Mobotinib is usually taken orally once daily, and the specific dosage and treatment time are determined by the doctor based on the patient's specific condition. Common side effects include diarrhea, rash, stomatitis, abnormal liver function and pneumonia. During treatment, patients should be regularly monitored by their doctor so that any possible side effects can be managed promptly.

Since its launch,mobotinib (mobosetinib)It has been shown to have significant efficacy in the treatment of NSCLC patients with exon 20 insertion mutations. Its research and development and clinical application not only fill the treatment gap in this field, but also provide patients with new hope for survival. With further research and clinical trials, the indications for mobosetinib may be further expanded to benefit more patients.